The structure of DNA in the nucleosome core, Nature, vol.423, pp.145-150, 2003. ,
The nucleosome: from genomic organization to genomic regulation, Cell, vol.116, pp.259-272, 2004. ,
Epigenomics and epigenetic therapy of cancer, Trends Mol. Med, vol.8, pp.43-48, 2002. ,
Chromatin modifications and their function, Cell, vol.128, pp.850-868, 2007. ,
Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents, Molecules, vol.20, pp.3898-3941, 2015. ,
Acetylation and deacetylation of non-histone proteins, Gene, vol.363, pp.15-23, 2005. ,
Histone deacetylase as a therapeutic target, Trends Endocrinol. Metab, vol.12, pp.294-300, 2001. ,
Histone deacetylases and transcriptional therapy with their inhibitors, Cancer Chemother. Pharm, vol.48, pp.17-19, 2001. ,
Class II histone deacetylases: from sequence to function, regulation, and clinical implication, Mol. Cell. Biol, vol.25, pp.2873-2884, 2005. ,
Histone deacetylases and cancer: causes and therapies, Nat. Rev. Cancer, vol.1, pp.194-202, 2001. ,
Histone deacetylases (HDACs): characterization of the classical HDAC family, Biochem. J, vol.370, pp.737-749, 2003. ,
The emerging role of class II histone deacetylases, Biochem. Cell. Biol, vol.79, pp.337-348, 2001. ,
Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis, J. Mol. Biol, vol.338, pp.17-31, 2004. ,
Histone modifications and chromatin dynamics: A focus on filamentous fungi, FEMS Microbiol. Rev, vol.32, pp.409-439, 2008. ,
Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer, Nat. Rev. Drug Discov, vol.1, pp.287-299, 2002. ,
The missing linker: an unexpected role for a histone deacetylase, Mol. Cell, vol.12, pp.1349-1351, 2003. ,
Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcription, Mol. Cell. Biol, vol.25, pp.10220-10234, 2005. ,
Histone-deacetylase inhibitors for the treatment of cancer, Cell Cycle, vol.3, pp.779-788, 2004. ,
Clinical development of histone deacetylase inhibitors as anticancer agents, Annu. Rev. Pharm. Toxicol, vol.45, pp.495-528, 2005. ,
Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis, Mol. Cell, vol.13, pp.627-638, 2004. ,
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors, J. Biol. Chem, vol.280, pp.26729-26734, 2005. ,
Rational development of histone deacetylase inhibitors as anticancer agents: a review, Mol. Pharm, vol.68, pp.917-932, 2005. ,
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor, Mol. Cell, vol.18, pp.601-607, 2005. ,
Histone acetyltransferases: challenges in targeting bi-substrate enzymes, Clin. Epigenet, vol.8, p.59, 2016. ,
The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60, Mol. Cell. Biol, vol.24, pp.10826-10834, 2004. ,
Histone acetyltransferases are crucial regulators in NF-kappaB mediated inflammation, Drug Discov. Today, vol.16, pp.504-511, 2011. ,
p300/CBP/p53 interaction and regulation of the p53 response, Eur. J. Biochem, vol.268, pp.850-869, 2001. ,
The binding of L-valyl-L-tryptophan to crystalline thermolysin illustrates the mode of interaction of a product of peptide hydrolysis, J. Biol. Chem, vol.263, pp.3256-3260, 1988. ,
Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes, Curr. Opin. Struct. Biol, vol.21, pp.735-743, 2011. ,
Structures of metal-substituted human histone deacetylase 8 provide mechanistic inferences on biological function, Biochemistry, vol.49, pp.5048-5056, 2010. ,
Activation and inhibition of histone deacetylase 8 by monovalent cations, J. Biol. Chem, vol.285, pp.6036-6043, 2010. ,
Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases, Structure, vol.12, pp.1325-1334, 2004. ,
Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex, EMBO Rep, vol.8, pp.879-884, 2007. ,
On the function of the internal cavity of histone deacetylase protein 8: R37 is a crucial residue for catalysis, Bioorg. Med. Chem. Lett, vol.21, pp.2129-2132, 2011. ,
The coregulator exchange in transcriptional functions of nuclear receptors, Genes Dev, vol.14, pp.121-141, 2000. ,
Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription, Nat. Genet, vol.19, pp.187-191, 1998. ,
Receptor-interacting protein 140 directly recruits histone deacetylases for gene silencing, J. Biol. Chem, vol.275, pp.40782-40787, 2000. ,
Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern, J. Biol. Chem, vol.279, pp.37175-37184, 2004. ,
DNA methyltransferase 3b regulates nerve growth factor-induced differentiation of PC12 cells by recruiting histone deacetylase 2, Mol. Cell. Biol, vol.25, pp.751-766, 2005. ,
DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters, Nat. Genet, vol.25, pp.338-342, 2000. ,
Retinoblastoma: clues to human oncogenesis, Science, vol.223, pp.1028-1033, 1984. ,
Retinoblastoma protein recruits histone deacetylase to repress transcription, Nature, vol.391, pp.597-601, 1998. ,
The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase, Proc. Natl. Acad. Sci, vol.95, pp.10493-10498, 1998. ,
Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition, Mol. Cell. Biol, vol.23, pp.7719-7731, 2003. ,
Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha, Int. J. Cancer, vol.107, pp.353-358, 2003. ,
A. pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer, Oncogene, vol.22, pp.3511-3517, 2003. ,
URL : https://hal.archives-ouvertes.fr/hal-02083496
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer, Nat. Genet, vol.37, p.29, 2005. ,
Histone acetylation and gastrointestinal carcinogenesis, Ann. N. Y. Acad. Sci, vol.983, pp.220-231, 2003. ,
Anticancer activities of histone deacetylase inhibitors, Nat. Rev. Drug Discov, vol.5, pp.769-784, 2006. ,
The role of histone deacetylases (HDACs) in human cancer, Mol. Oncol, vol.1, pp.19-25, 2007. ,
Retinoids regulate stem cell differentiation, J. Cell. Physiol, vol.226, pp.322-330, 2011. ,
Transcriptional regulation in acute promyelocytic leukemia, Oncogene, vol.20, pp.7204-7215, 2001. ,
Expression profile of histone deacetylase 1 in gastric cancer tissues, Jpn. J. Cancer Res, vol.92, pp.1300-1304, 2001. ,
Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer, Prostate, vol.59, pp.177-189, 2004. ,
Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer, J. Biol. Chem, vol.281, pp.13548-13558, 2006. ,
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast, Breast Cancer Res. Treat, vol.94, pp.11-16, 2005. ,
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1, Cell Death Differ, vol.12, pp.395-404, 2005. ,
Increased expression of histone deacetylase 2 is found in human gastric cancer, APMIS, vol.113, pp.264-268, 2005. ,
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis, Cancer Cell, vol.5, pp.455-463, 2004. ,
HDAC6 expression is correlated with better survival in breast cancer, Clin. Cancer Res, vol.10, pp.6962-6968, 2004. ,
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1, Proc. Natl. Acad. Sci, vol.101, pp.1241-1246, 2004. ,
Histone deacetylase inhibitors: signalling towards p21cip1/waf1, Int. J. Biochem. Cell Biol, vol.39, pp.1367-1374, 2007. ,
DNA topoisomerase II poison TAS-103 transactivates GC-box-dependent transcription via acetylation of Sp1, J. Biol. Chem, vol.280, pp.1179-1185, 2005. ,
Transcription factor Sp3 is regulated by acetylation, Nucleic. Acids Res, vol.29, pp.4994-5000, 2001. ,
Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL, J. Neurooncol, vol.93, pp.303-318, 2009. ,
Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells, Cancer Res, vol.64, pp.2580-2589, 2004. ,
DR4 mediates the progression, invasion, metastasis and survival of colorectal cancer through the Sp1/NF1 switch axis on genomic locus, Int. J. Cancer, vol.143, pp.850-871, 2018. ,
Quercetin enhances the antitumor activity of trichostatin A through up-regulation of p300 protein expression in p53 null cancer cells, Chem. Biol. Interact, vol.306, pp.54-61, 2019. ,
Ku70 acetylation and modulation of c-Myc/ATF4/CHOP signaling axis by SIRT1 inhibition lead to sensitization of HepG2 cells to TRAIL through induction of DR5 and down-regulation of c-FLIP, Int. J. Biochem. Cell Biol, vol.45, pp.711-723, 2013. ,
Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells, Carcinogenesis, vol.25, pp.1813-1820, 2004. ,
Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1, Mol. Cell. Biol, vol.25, pp.5404-5416, 2005. ,
Sp1 phosphorylation regulates apoptosis via extracellular FasL-Fas engagement, J. Biol. Chem, vol.276, pp.4964-4971, 2001. ,
FasL promoter activation by IL-2 through SP1 and NFAT but not Egr-2 and Egr-3, Eur J. Immunol, vol.29, pp.3456-3465, 1999. ,
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer, Nat. Rev. Cancer, vol.6, pp.38-51, 2006. ,
Sirtuins in metabolism, DNA repair and cancer, J. Exp. Clin. Cancer Res, vol.35, 2016. ,
Sirtuin-3 (SIRT3) and the Hallmarks of Cancer, Genes Cancer, vol.4, pp.164-171, 2013. ,
Sirtuin-4 (SIRT4), a therapeutic target with oncogenic and tumor-suppressive activity in cancer, vol.11, pp.3395-3400, 2018. ,
SIRT2: tumour suppressor or tumour promoter in operable breast cancer?, Eur J. Cancer, vol.50, pp.290-301, 2014. ,
Tumour-suppressive function of SIRT4 in human colorectal cancer, Br. J. Cancer, vol.113, pp.492-499, 2015. ,
Molecular pathways: emerging roles of mammalian Sirtuin SIRT7 in cancer, Clin. Cancer Res, vol.20, pp.1741-1746, 2014. ,
The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism, Cell, vol.151, pp.1185-1199, 2012. ,
SIRT7 antagonizes TGF-beta signaling and inhibits breast cancer metastasis, Nat. Commun, vol.8, p.318, 2017. ,
Oncogene and tumor suppressor in cancer, vol.9, p.90, 2017. ,
SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer, Oncol. Rep, vol.39, pp.2315-2323, 2018. ,
Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation, PLOS Genet, vol.2, 2006. ,
Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin, Mol. Cell, vol.16, pp.93-105, 2004. ,
Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase, EMBO J, vol.23, pp.2369-2380, 2004. ,
, Cancers, vol.11, pp.850-872, 2019.
Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation, Proc. Natl. Acad. Sci, vol.102, pp.1859-1864, 2005. ,
Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors, Leukemia, vol.19, pp.1751-1759, 2005. ,
Differential expression of selected histone modifier genes in human solid cancers, BMC Genom, vol.7, p.90, 2006. ,
Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses, Cell, vol.123, pp.437-448, 2005. ,
SIRT1 promotes DNA repair activity and deacetylation of Ku70, Exp. Mol. Med, vol.39, pp.8-13, 2007. ,
SIRT1 inhibition impairs non-homologous end joining DNA damage repair by increasing Ku70 acetylation in chronic myeloid leukemia cells, Oncotarget, vol.7, pp.13538-13550, 2016. ,
HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases, Biomed. Res. Int, vol.8797206, 2016. ,
Sensitization of tumor cells by targeting histone deacetylases, Biochem. Pharm, vol.83, pp.987-994, 2012. ,
Deacetylation of nonhistone proteins by HDACs and the implications in cancer, Handb. Exp. Pharm, vol.206, pp.39-56, 2011. ,
Histone deacetylase inhibitors as anticancer drugs, Int. J. Mol. Sci, vol.18, 1414. ,
Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia, Br. J. Cancer, vol.114, pp.605-611, 2016. ,
A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity, Curr. Med. Chem, vol.21, pp.2642-2664, 2014. ,
Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group, Nat. Chem. Biol, vol.9, pp.319-325, 2013. ,
Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report, Clin. Cancer Res, vol.17, pp.589-597, 2011. ,
Histone deacetylase inhibitor sulforaphane: The phytochemical with vibrant activity against prostate cancer, Biomed. Pharm, vol.81, pp.250-257, 2016. ,
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma, Oncologist, vol.12, pp.1247-1252, 2007. ,
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma, J. Clin. Oncol, vol.27, pp.5410-5417, 2009. ,
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma, J. Clin. Oncol, vol.28, pp.4485-4491, 2010. ,
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma, Br. J. Haematol, vol.168, pp.811-819, 2015. ,
Sirtuins as regulators of metabolism and healthspan, Nat. Rev. Mol. Cell. Biol, vol.13, pp.850-873, 2012. ,
Anticancer agents targeted to sirtuins, Molecules, vol.19, pp.20295-20313, 2014. ,
Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity, J. Med. Chem, vol.52, pp.2673-2682, 2009. ,
Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties, PLoS ONE, vol.10, 2015. ,
Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice, J. Clin. Investig, vol.118, pp.3588-3597, 2008. ,
Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi1 leukemia cells, Mol. Med. Rep, vol.9, pp.443-449, 2014. ,
Suberoylanilide hydroxamic acid suppresses inflammation-induced neovascularization. Can, J. Physiol. Pharm, vol.92, pp.879-885, 2014. ,
Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells, Leuk. Res, vol.32, pp.771-780, 2008. ,
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1, Cancer Res, vol.63, pp.3637-3645, 2003. ,
The thioredoxin-thioredoxin reductase system: over-expression in human cancer, Anticancer Res, vol.23, pp.2425-2433, 2003. ,
Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells, Cell Stress Chaperones, vol.20, pp.149-157, 2015. ,
Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro-and antiapoptotic proteins, Mol. Med, vol.14, pp.20-27, 2008. ,
Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway?, Exp. Mol. Med, vol.38, pp.616-624, 2006. ,
HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis, Cancer Lett, vol.297, pp.91-100, 2010. ,
Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways, Int. J. Mol. Med, vol.16, pp.1125-1138, 2005. ,
Cancer epigenetics: from mechanism to therapy, Cell, vol.150, pp.12-27, 2012. ,
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses, Cell Death Dis, 2013. ,
Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis, Cell Death Differ, vol.13, pp.129-140, 2006. ,
Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma, Neoplasia, vol.7, pp.646-657, 2005. ,
Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells, Apoptosis, vol.11, pp.2251-2265, 2006. ,
Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells, J. Mol. Med, vol.91, pp.49-58, 2013. ,
HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma, Eur. J. Med. Res, 2016. ,
Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas, Mol. Cell. Biol, vol.25, pp.1608-1619, 2005. ,
ATF3 repression of BCL-XL determines apoptotic sensitivity to HDAC inhibitors across tumor types, Clin. Cancer Res, vol.23, pp.5573-5584, 2017. ,
The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells, Mol. Cancer, vol.3, pp.425-435, 2004. ,
Modulation of pro-and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors, Apoptosis, vol.9, pp.573-582, 2004. ,
WMJ-8-B, a novel hydroxamate derivative, induces MDA-MB-231 breast cancer cell death via the SHP-1-STAT3-survivin cascade, Br. J. Pharm, vol.174, pp.2941-2961, 2017. ,
Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin, J. Pharm. Exp, vol.304, pp.881-888, 2003. ,
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway, Nat. Med, vol.11, pp.71-76, 2005. ,
Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells, Am. J. Physiol. Gastrointest. Liver Physiol, vol.302, pp.1405-1415, 2012. ,
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells, Nat. Med, vol.11, pp.77-84, 2005. ,
URL : https://hal.archives-ouvertes.fr/hal-00187707
Predicting aberrant CpG island methylation, Proc. Natl. Acad. Sci, vol.100, pp.12253-12258, 2003. ,
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns, Nat. Genet, vol.24, pp.132-138, 2000. ,
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer, Genome Res, vol.20, pp.440-446, 2010. ,
Corruption of the intra-gene DNA methylation architecture is a hallmark of cancer, PLoS ONE, vol.8, 2013. ,
Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding, Cell, vol.176, pp.98-112, 2019. ,
, Blood, vol.93, pp.4059-4070, 1999.
The fundamental role of epigenetic events in cancer, Nat. Rev. Genet, vol.3, pp.415-428, 2002. ,
Frequent hypermethylation of orphan CpG islands with enhancer activity in cancer, BMC Med. Genom, vol.2016 ,
Methylation matters, J. Med. Genet, vol.38, pp.285-303, 2001. ,
The roles of human DNA methyltransferases and their isoforms in shaping the epigenome, Genes (Basel), vol.10, p.172, 2019. ,
Local chromatin microenvironment determines DNMT activity: from DNA methyltransferase to DNA demethylase or DNA dehydroxymethylase, Epigenetics, vol.10, pp.671-676, 2015. ,
Active DNA demethylation of the vertebrate genomes by DNA methyltransferases: deaminase, dehydroxymethylase or demethylase?, Epigenomics, vol.6, pp.353-363, 2014. ,
, The TET enzymes. Cell. Mol. Life Sci, vol.75, pp.1339-1348, 2018.
TET enzymes, TDG and the dynamics of DNA demethylation, Nature, vol.502, pp.472-479, 2013. ,
DNA demethylases: a new epigenetic frontier in drug discovery, Drug Discov. Today, vol.16, pp.683-690, 2011. ,
Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy, ISRN Oncol, 2013. ,
The TNF-family cytokine TL1A inhibits proliferation of human activated B cells, PLoS ONE, vol.8, 2013. ,
The TNF family member 4-1BBL sustains inflammation by interacting with TLR signaling components during late-phase activation, Sci. Signal, issue.6, 2013. ,
Posttranslational modifications and death receptor signalling, TRAIL, Fas Ligand, TNF and TLR3 in Cancer, 2017. ,
Regulation of TNF-related apoptosis-inducing ligand signaling by glycosylation, Int. J. Mol. Sci, vol.19, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-01722814
Marine drugs regulating apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), Mar. Drugs, vol.13, pp.6884-6909, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01231327
Towards novel paradigms for cancer therapy, Oncogene, vol.30, pp.1-20, 2011. ,
Intracellular mechanisms of TRAIL and its role in cancer therapy, Mol. Cell. Biol. Res. Commun, vol.4, pp.67-75, 2000. ,
Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis, Science, vol.345, pp.98-101, 2014. ,
TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress, Oncotarget, vol.8, pp.9974-9985, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01423110
Glucose deprivation induces ATF4-mediated apoptosis through TRAIL death receptors, Mol. Cell. Biol, vol.37, 2017. ,
Endoplasmic reticulum stress induces ligand-independent TNFR1-mediated necroptosis in L929 cells, Cell Death Dis, vol.6, 1587. ,
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo, Nat. Med, vol.5, pp.157-163, 1999. ,
Death receptors as targets in cancer, Br. J. Pharm, vol.169, pp.1723-1744, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-00823459
How melanoma cells evade trail-induced apoptosis, Nat. Rev. Cancer, vol.1, pp.142-150, 2001. ,
Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma, Cancer Res, vol.59, pp.4392-4399, 1999. ,
Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells, J. Biol. Chem, vol.277, pp.2073-2080, 2002. ,
Impact of the DNA methyltransferases expression on the methylation status of apoptosis-associated genes in glioblastoma multiforme ,
CpG island methylation of DNA damage response genes in advanced ovarian cancer, Cancer Res, vol.65, pp.8961-8967, 2005. ,
Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis, BMC Cancer, vol.2, p.29, 2002. ,
Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma, BMC Cancer, vol.4, 2004. ,
Aberrant DNA methylation of apoptotic signaling genes in patients responsive and nonresponsive to therapy for cervical carcinoma, Am. J. Obs. Gynecol, vol.202, 2010. ,
Survivin: A molecular biomarker in cancer, Indian J. Med. Res, vol.141, pp.389-397, 2015. ,
Therapeutic strategies involving survivin inhibition in cancer, Med. Res. Rev, vol.39, pp.887-909, 2019. ,
DNA methylation inhibits p53-mediated survivin repression, Oncogene, vol.28, pp.2046-2050, 2009. ,
Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL, Carcinogenesis, vol.32, pp.1450-1458, 2011. ,
XAF1 mediates tumor necrosis factor-alpha-induced apoptosis and X-linked inhibitor of apoptosis cleavage by acting through the mitochondrial pathway, J. Biol. Chem, vol.282, pp.13059-13072, 2007. ,
Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN-beta, BMC Cancer, vol.7, p.52, 2007. ,
Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis, Cancer Res, vol.60, pp.4315-4319, 2000. ,
Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing, Invest. Ophthalmol. Vis. Sci, vol.46, pp.358-366, 2005. ,
Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferential 11p15.5 maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas, Endocr. Relat. Cancer, vol.12, pp.161-172, 2005. ,
Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression, Cancer Res, vol.61, pp.1314-1319, 2001. ,
5-Aza-2 -deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8, Oncogene, vol.25, pp.5125-5133, 2006. ,
Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation, Cell Death Differ, vol.10, pp.356-364, 2003. ,
Epigenetic methylation and expression of caspase 8 and survivin in hepatocellular carcinoma, Pathol. Int, vol.60, pp.203-211, 2010. ,
DNMT1 and DNMT3b silencing sensitizes human hepatoma cells to TRAIL-mediated apoptosis via up-regulation of TRAIL-R2/DR5 and caspase-8, Cancer Sci, vol.101, pp.1431-1439, 2010. ,
GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma, BMC Cancer, vol.12, 2012. ,
Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation, Cancer Res, vol.62, pp.2157-2161, 2002. ,
Clustering of hypermethylated genes in neuroblastoma, Genes Chromosomes Cancer, vol.38, pp.226-233, 2003. ,
Investigation of DNA damage response and apoptotic gene methylation pattern in sporadic breast tumors using high throughput quantitative DNA methylation analysis technology, Mol. Cancer, vol.9, p.303, 2010. ,
Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer, Genes Chromosomes Cancer, vol.55, pp.177-189, 2016. ,
Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas, Clin. Cancer Res, vol.15, pp.5457-5465, 2009. ,
Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma, Biochem. Biophys. Res. Commun, vol.441, pp.743-750, 2013. ,
Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression, Mol. Cancer, vol.9, 2010. ,
Discovery and characterization of Isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to TRAIL in cancer cells, Oncotarget, vol.7, pp.24027-24049, 2016. ,
,
Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy, Cell Death Differ, vol.23, pp.1886-1896, 2016. ,
The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis, Biochem. Pharm, vol.66, pp.1537-1545, 2003. ,
Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance, Am. J. Clin. Exp. Immunol, vol.2, pp.55-74, 2013. ,
Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway, J. Immunol, vol.192, pp.3981-3989, 2014. ,
Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis, Mol. Cancer, vol.8, pp.3088-3097, 2009. ,
A histone deacetylase inhibitor analogue of FR235222, sensitizes promyelocytic leukaemia U937 cells to TRAIL-mediated apoptosis, Anticancer Res, vol.30, pp.887-894, 2010. ,
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist, Proc. Natl Acad. Sci, vol.105, pp.11317-11322, 2008. ,
Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP, Oncogene, vol.24, pp.6877-6889, 2005. ,
Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro-to anti-apoptotic proteins ratio, BMC Cancer, vol.6, 2006. ,
Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95-and TRAIL receptor-mediated apoptosis and chemotherapy, Oncol Rep, vol.15, pp.227-230, 2006. ,
The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation, Eur. J. Cancer, vol.45, pp.2425-2438, 2009. ,
Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells, Cancer Res, vol.66, pp.499-507, 2006. ,
Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation, Mol. Carcinog, vol.57, pp.1492-1506, 2018. ,
Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteins, Cancer Chemother. Pharm, vol.58, pp.471-477, 2006. ,
Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells, Oncogene, vol.23, pp.6261-6271, 2004. ,
Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis, Anticancer Res, vol.28, pp.855-864, 2008. ,
Epigenetic silencing of apoptosis-inducing gene expression can be efficiently overcome by combined SAHA and TRAIL treatment in uterine sarcoma cells, PLoS ONE, vol.9, 2014. ,
HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL, Hepatology, vol.43, pp.425-434, 2006. ,
Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8, Oncogene, vol.28, pp.3097-3110, 2009. ,
Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands, Mol. Cancer, vol.9, pp.246-256, 2010. ,
Trailing TRAIL resistance: Novel targets for TRAIL sensitization in cancer cells, Front. Oncol, vol.5, p.69, 2015. ,
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma, Nat. Med, vol.21, pp.1163-1171, 2015. ,
Preclinical studies support combined inhibition of BET family proteins and histone deacetylases as epigenetic therapy for cutaneous T-cell lymphoma, Neoplasia, vol.21, pp.82-92, 2019. ,
Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents, Cell Death Dis, 2016. ,
The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition, Oncotarget, vol.6, pp.34669-34679, 2015. ,
Inhibition of death receptor signals by cellular FLIP, Nature, vol.388, pp.190-195, 1997. ,
dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8, Cell Death Differ, vol.19, pp.1482-1494, 2012. ,
Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP, Oncogene, vol.31, pp.4677-4688, 2012. ,
SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells, Biochimie, vol.94, pp.287-299, 2012. ,
The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases, Curr. Cancer Drug Targets, vol.13, pp.411-422, 2013. ,
Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells, Apoptosis, vol.15, pp.1256-1269, 2010. ,
Venza, I. miR-92a-3p and MYCBP2 are involved in MS-275-induced and c-myc-mediated TRAIL-sensitivity in melanoma cells, Int. Immunopharmacol, vol.40, pp.235-243, 2016. ,
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation, Clin. Cancer Res, vol.14, pp.5385-5399, 2008. ,
Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis, Cell Death Differ, vol.19, pp.1317-1327, 2012. ,
Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells, J. Cell. Mol. Med, vol.16, pp.1618-1628, 2012. ,
Homoharringtonine and SAHA synergistically enhance apoptosis in human acute myeloid leukemia cells through upregulation of TRAIL and death receptors, Mol. Med. Rep, vol.7, pp.1838-1844, 2013. ,
, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, © 2019 by the authors. Licensee MDPI